查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2001117

肺癌免疫疗法查核点抑制剂市场：2026-2032年全球市场预测（按癌症类型、通路、治疗方法、作用机制、治疗阶段和最终用户划分）

Immune Checkpoint Inhibitors for Lung Cancer Market by Cancer Type, Distribution Channel, Treatment Regimen, Mechanism Of Action, Line Of Therapy, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肺癌免疫查核点抑制剂市场价值将达到 13.2 亿美元，到 2026 年将成长到 15.2 亿美元，到 2032 年将达到 35.5 亿美元，复合年增长率为 15.08%。

主要市场统计数据
基准年 2025 13.2亿美元
预计年份：2026年 15.2亿美元
预测年份：2032年 35.5亿美元
复合年增长率 (%) 15.08%

本报告概述了临床进展、相关人员的优先事项和关键决策点，介绍了肺癌免疫查核点抑制剂的策略背景。

免疫查核点抑制剂从根本上改变了肺癌的治疗模式，使治疗策略从单纯的细胞毒性疗法转向以靶向免疫调节为导向、旨在带来持续临床获益的疗法。在过去十年间，临床医生和研究人员加深了对肿瘤与免疫系统相互作用的理解，并将这些发现应用于治疗，激活抗肿瘤免疫，从而改善了许多患者的生存和生活品质。

我们将找出正在重塑肺癌免疫疗法的变革性变化，包括基于生物标记的治疗、联合治疗以及监管和保险公司的趋势。

目前，肺癌免疫疗法正经历多项相互促进的变革，这些变革正在改变治疗方法的研发、评估和实施方式。首先，临床实践正朝着精准免疫肿瘤学的方向发展，基于生物标记（例如PD-L1表达和更广泛的基因组特征）的选择正成为治疗方法选择和临床试验入组决策的关键因素。因此，适应性队列和基于生物标记的筛选组正越来越多地被纳入临床试验设计，以提高讯号检测的准确性并加快监管决策。

评估 2025 年美国新关税措施对肺癌免疫疗法的供应链、临床计画和商业性取得的累积影响。

影响跨境贸易的政策可能会对整个药物研发和商业化生态系统产生连锁反应。提案的2025年关税调整将为免疫查核点抑制剂计画带来复杂的营运和经济挑战。进口生物材料、特殊试剂或成品的关税增加可能会推高产品单价，迫使製造商重新评估其筹资策略和契约製造关係。为此，申办方可能会加快供应链在地化进程，重新谈判长期供应商协议，或实现供应商多元化，以降低单一来源的风险。

我们分析癌症类型、通路、治疗方法、作用机制、治疗线和最终用户等方面的见解，以优化市场定位。

在肺癌这一高度多样化的领域，深入了解肺癌的细分对于优化研发和商业化策略至关重要。就癌症类型而言，非小细胞肺癌和小细胞肺癌之间的差异会影响临床试验的设计、监管终点和製剂方案。在非小细胞肺癌中，非鳞状细胞癌和鳞状细胞癌的组织学差异决定了预期疗效和安全性。此外，非鳞状细胞癌内部的亚型细分，例如腺癌和大细胞癌，揭示了生物标记的普遍性以及与标靶治疗的潜在相互作用。

美洲、欧洲、中东和非洲以及亚太地区的优先事项和不同的部署路径，影响产品的取得和商业化。

临床实务、监管方式和医疗基础设施的区域差异对免疫查核点抑制剂的引入和应用产生了显着影响。在美洲，完善的医保报销管道、强大的肿瘤网络和高水平的临床试验能力支持新治疗方法的快速推广，但成本控制和支付方对疗效的严格审查仍然是持续的挑战。该地区的市场进入策略通常结合可靠的III期临床试验证据和真实世界临床数据，以确保药物被纳入医保覆盖范围并获得有利的准入政策。

根据公司层面的洞察，竞争考察和合作洞察是决定肺癌免疫疗法领域领导地位的关键因素。

肺癌免疫疗法领域的企业策略正朝着几个共同的方向发展：差异化的临床定位、策略联盟、产品组合的广度以及实证医学能力。优先发展强大的生物标记计画和建立伴随诊断联盟的企业，能够更好地掌握临床定义的、疗效最为显着的亚群人群。投资于联合治疗研究并有效管理早期安全性讯号的企业，则能够显着区别于单药疗法。

产业领导者为加速免疫疗法的发展、扩大应用范围以及建立强大的商业和临床管道而提​​出的实用建议。

产业领导者可以透过推动一系列切实可行且优先的措施来加速发展并降低商业化风险。首先，透过将研发项目组合与生物标记定义的适应症相匹配，并儘早开发伴随核准策略，简化监管审批流程并改善患者筛选。同时，设计包含适应性要素和以病人为中心的有意义终点的联合治疗试验，以展现超越传统生存指标的价值。其次，投资于分散式和混合式临床试验模式，以产生更具代表性的真实世界数据，从而扩大受试者招募范围、提高受试者保留率并支持与支付方的对话。

一套严谨的调查方法，详细说明了用于产生可靠市场资讯的证据来源、专家参与、三角验证和限制。

本报告的分析整合了多种证据来源，得出严谨而令人信服的结论。二次研究包括同行评审的临床文献、监管指导文件和公开的临床实验室註册数据，揭示了治疗机制、安全性概况和实验室设计。为了补充这些资讯来源，我们也对肿瘤学家、临床实验室医生、卫生经济学专家、监管专家和供应链负责人进行了结构化访谈，以了解实际应用经验和营运挑战。

对肺癌免疫疗法领域的相关人员，从临床创新、政策转变和营运重点中获得的策略见解进行了具体化的总结。

科学创新、策略性商业化策略和不断变化的政策正在改变肺癌治疗中免疫查核点抑制剂的研发和应用。临床上，儘管基于生物标记的患者筛选和联合治疗正在改善治疗效果，但安全性管理和实验室设计方面也出现了新的复杂性。在营运上，分销管道的选择和终端用户的接受度会影响药物的可及性，而稳健的供应链对于维持治疗的连续性至关重要，即使面临政策变化也能确保治疗的持续性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：肺癌免疫查核点抑制剂市场：依癌症类型划分

  • 癌症
    • 非小细胞肺癌
      • 非鳞状
      • 腺癌
      • 大细胞癌
      • 鳞状上皮
    • 小细胞肺癌

第九章：肺癌免疫疗法查核点抑制剂市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房
  • 专科药房

第十章：肺癌免疫查核点抑制剂市场：依治疗方法

  • 联合治疗
    • 合併化疗
    • 联合标靶治疗治疗
  • 单药治疗

第十一章 肺癌免疫疗法查核点抑制剂市场：依作用机制划分

  • CTLA-4抑制剂
  • PD-1抑制剂
    • 半原发
    • Nivolumab
    • Pembrolizumab

第十二章 肺癌免疫查核点抑制剂市场：依治疗阶段划分

  • 第 1 行
  • 第二行
  • 从第三行开始

第十三章 肺癌免疫疗法查核点抑制剂市场：依最终用户划分

  • 门诊手术中心
  • 居家照护设施
  • 医院
  • 肿瘤诊所

第十四章 肺癌免疫疗法查核点抑制剂市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：肺癌免疫疗法查核点抑制剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 肺癌免疫疗法查核点抑制剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国肺癌免疫查核点抑制剂市场

第十八章：中国肺癌免疫查核点抑制剂市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeyondSpring Pharmaceuticals Inc.
  • BioLineRx Ltd.
  • BridgeBio Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • IQVIA Inc.
  • Jazz Pharmaceuticals
  • Mirati Therapeutics Inc.
  • Ono Pharmaceutical Co. Ltd
  • Philogen SpA
Product Code: MRR-E40E525C3802

The Immune Checkpoint Inhibitors for Lung Cancer Market was valued at USD 1.32 billion in 2025 and is projected to grow to USD 1.52 billion in 2026, with a CAGR of 15.08%, reaching USD 3.55 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.32 billion
Estimated Year [2026] USD 1.52 billion
Forecast Year [2032] USD 3.55 billion
CAGR (%) 15.08%

Setting the strategic context for immune checkpoint inhibitors in lung cancer by outlining clinical advances, stakeholder priorities, and decision-making imperatives

Immune checkpoint inhibitors have fundamentally altered the treatment paradigm for lung cancer, moving therapeutic strategy from cytotoxic-only approaches to targeted immune modulation that aims to deliver durable clinical benefit. Over the past decade, clinicians and researchers have advanced our understanding of tumor-immune interactions, translating those discoveries into therapeutics that reinvigorate antitumor immunity and alter survival and quality-of-life considerations for many patients.

This introduction frames the clinical, operational, and commercial dimensions that stakeholders must weigh when evaluating immune checkpoint inhibitor programs. Clinically, integrating biomarker testing, refining patient selection, and optimizing sequencing with chemotherapy and targeted agents remain primary considerations for therapeutic teams. Operationally, the complexity of introducing biologic therapies influences distribution choices, cold-chain logistics, and infusion capacity planning across hospitals and ambulatory settings. Commercially, alignment with payers, evidence generation to support reimbursement, and differentiated positioning based on mechanism of action and line of therapy are central to adoption strategies.

As you read further, the analysis that follows synthesizes clinical progress, regulatory posture, and system-level pressures to present a balanced view of opportunities and risks. The goal is to equip decision-makers with a clear, concise foundation for prioritizing investments and partnerships that will accelerate meaningful patient impact.

Identifying transformative shifts reshaping lung cancer immunotherapy including biomarker-driven care, combination approaches, and regulatory and payer dynamics

The landscape for lung cancer immunotherapy is in the midst of several concurrent and reinforcing shifts that are changing how therapies are developed, evaluated, and delivered. First, clinical practice has moved toward precision immuno-oncology where biomarker-driven selection-such as PD-L1 expression and broader genomic signatures-informs therapeutic choice and trial enrollment. Consequently, trial designs increasingly embed adaptive cohorts and biomarker-enriched arms to improve signal detection and expedite regulatory decision-making.

Second, combination strategies are now a core development focus, pairing checkpoint inhibitors with chemotherapy, targeted agents, or other immune modulators to address resistance mechanisms and enhance response durability. These combinations require new safety management paradigms and novel clinical endpoints, which in turn influence regulatory engagement and payer evidence expectations. Third, regulatory agencies and payers are placing greater emphasis on real-world evidence and health-economic outcomes, prompting sponsors to invest in longitudinal data collection and outcomes research alongside classical randomized trials.

Fourth, manufacturing and supply chain considerations are driving investment in scalable biologics production and cold-chain logistics. At the same time, digital health tools and decentralized trial methodologies are improving patient access and retention, expanding the potential study population beyond traditional academic centers. Taken together, these shifts are creating an environment where agility in clinical strategy, data generation, and stakeholder engagement will determine which therapies achieve broad adoption and meaningful patient benefit.

Assessing the cumulative impact of new United States tariff policies in 2025 on lung cancer immunotherapy supply chains, clinical programs, and commercial access

Policy actions that affect cross-border trade can reverberate across the drug development and commercialization ecosystem, and proposed tariff changes in 2025 present a complex set of operational and economic considerations for immune checkpoint inhibitor programs. Higher duties on imported biologic materials, specialized reagents, or finished products can increase the unit cost of goods, potentially pressuring manufacturers to reevaluate sourcing strategies and contract manufacturing relationships. In response, sponsors may accelerate localization of supply chains, renegotiate long-term supplier agreements, or diversify suppliers to mitigate single-source risks.

Clinical development is sensitive to supply interruptions and cost volatility. Tariff-driven increases in the cost of clinical supplies or delays at customs can complicate trial logistics, particularly for multicenter studies that rely on synchronized drug shipments. Sponsors can mitigate this risk by building buffer inventories, qualifying multiple depots, and leveraging regional manufacturing hubs where feasible. Meanwhile, commercial access strategies may need to adapt as payers scrutinize price increases; transparent communication about cost drivers and evidence of clinical value will be critical to maintaining formulary positions.

Finally, the policy environment can incentivize strategic partnerships and vertical integration, encouraging companies to explore regional production or licensing arrangements that preserve margins and secure supply. While tariffs add a layer of complexity, proactive operational planning, scenario-based financial modeling, and early engagement with regulatory and customs authorities can reduce disruption and preserve patient access to critical immunotherapies.

Decoding segmentation-driven insights across cancer type, distribution channel, treatment regimen, mechanism, line of therapy, and end user to optimize positioning

A fine-grained understanding of segmentation is essential for tailoring development and commercialization approaches across the heterogeneous lung cancer landscape. When considering cancer type, distinctions between Non-Small Cell Lung Cancer and Small Cell Lung Cancer drive different clinical trial designs, regulatory endpoints, and prescribing patterns, while within Non-Small Cell Lung Cancer the split between Non-Squamous and Squamous histologies shapes expected responses and safety profiles. Further subclassification such as Adenocarcinoma and Large Cell Carcinoma under Non-Squamous informs biomarker prevalence and the likely interaction with targeted therapies.

Distribution channel choices-from hospital pharmacy to online pharmacy, retail pharmacy, and specialty pharmacy-determine the logistics model, patient support structures, and reimbursement pathways. The treatment regimen axis separates monotherapy from combination therapy, and when combinations include chemotherapy or targeted therapy the clinical development strategy must address additive toxicities and regimen sequencing. End user segmentation across ambulatory surgical centers, home care settings, hospitals, and oncology clinics influences site readiness, infusion capacity, and the design of patient navigation services.

Mechanism of action segmentation differentiates CTLA-4 inhibitors from PD-1 and PD-L1 inhibitors, with specific agents such as ipilimumab, cemiplimab, nivolumab, pembrolizumab, atezolizumab, and durvalumab offering distinct clinical profiles that matter for labeling and positioning. Finally, line-of-therapy distinctions between first line, second line, and third or later determine the competitive set and the evidence bar required to displace incumbents. Integrating these segmentation dimensions allows sponsors to prioritize clinical programs, channel strategies, and evidence generation to match the needs of distinct patient populations and care settings.

Regional priorities and differentiated adoption trajectories across Americas, Europe, Middle East & Africa, and Asia-Pacific that influence access and commercialization

Regional variation in clinical practice, regulatory approach, and healthcare infrastructure materially affects how immune checkpoint inhibitors are adopted and scaled. In the Americas, established reimbursement pathways, strong oncology networks, and high clinical trial capacity support rapid uptake of novel regimens, though cost containment and payer scrutiny of value remain constant considerations. Market access strategies in this region often combine robust phase III evidence with real-world outcomes to secure formulary placement and favorable utilization policies.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and payer models requires a nuanced approach that accounts for national health technology assessment processes, variable reimbursement timelines, and differing logistical capacities. Engagement with regional health authorities and local stakeholders is essential to align clinical evidence packages with country-specific value frameworks. In Asia-Pacific, the diversity of health systems spans advanced markets with accelerated adoption to emerging markets where access constraints and infrastructure gaps necessitate adaptive distribution and patient support programs. Manufacturing localization and strategic partnerships can be especially impactful in this region to improve affordability and supply reliability.

Across all regions, tailoring evidence generation to local decision drivers, investing in clinician education, and designing flexible distribution models are core imperatives. Cross-regional coordination can unlock efficiencies in global development while allowing targeted adaptations for local regulatory and payer landscapes.

Competitive and collaborative company-level insights revealing where innovation, partnerships, and portfolio strategies will determine leadership in lung cancer immunotherapy

Company strategies in lung cancer immunotherapy are converging around several themes: differentiated clinical positioning, strategic alliances, portfolio breadth, and capabilities in evidence generation. Firms that prioritize robust biomarker programs and companion diagnostic partnerships position themselves to capture clinically defined subpopulations where therapeutic benefit is most pronounced. Companies that invest in combination science and manage early safety signals effectively can create compelling differentiation versus monotherapy options.

Strategic collaborations-ranging from research partnerships with biotechnology innovators to co-development agreements with makers of targeted agents-accelerate access to complementary mechanisms and expand clinical options for resistant disease. Firms that build integrated capabilities in real-world evidence generation, health economics, and outcomes research strengthen payer discussions and facilitate reimbursement negotiations. Meanwhile, investments in scalable biologics manufacturing and geographically diversified supply chains reduce operational risk and can support more predictable commercialization rollouts.

Competitive positioning also rests on commercial execution, with leaders offering comprehensive patient support programs, education for treating physicians, and adaptive pricing strategies that reflect value-based outcomes. Companies that combine strong clinical data with operational excellence and payor-aligned value propositions will be best placed to sustain adoption and long-term utilization across diverse care settings.

Actionable recommendations for industry leaders to accelerate development, enhance access, and build resilient commercial and clinical pathways in immunotherapy

Industry leaders can accelerate progress and de-risk commercialization by pursuing a set of actionable, prioritized initiatives. First, align R&D portfolios with biomarker-defined indications and develop companion diagnostic strategies early to streamline regulatory pathways and improve patient selection. Concurrently, design combination trials that incorporate adaptive elements and meaningful patient-centric endpoints to demonstrate value beyond traditional survival metrics. Second, invest in decentralized and hybrid trial models to broaden recruitment, enhance retention, and generate more representative real-world evidence that supports payer dialogues.

Third, fortify supply chains through supplier diversification, regional manufacturing options, and inventory strategies that reduce exposure to trade disruptions and policy shocks. Fourth, engage payers proactively with transparent value dossiers and outcomes-based contracting where appropriate to address affordability concerns while protecting access. Fifth, build differentiated patient support programs that facilitate adherence, manage immune-related adverse events, and enable treatment continuity across hospitals, oncology clinics, home care settings, and specialty pharmacies.

Finally, cultivate strategic partnerships with diagnostics firms, academic centers, and contract research organizations to accelerate translational science and speed clinical development. By implementing these recommendations, leaders will enhance the likelihood of successful product launches, sustainable access, and measurable improvements in patient outcomes.

Robust research methodology detailing evidence sources, expert engagement, triangulation methods, and limitations used to produce defensible market intelligence

The analysis underpinning this report integrates multiple evidence streams to ensure rigorous, defensible conclusions. Secondary research included peer-reviewed clinical literature, regulatory guidance documents, and publicly available clinical trial registries to map therapeutic mechanisms, safety profiles, and trial designs. To complement these sources, structured interviews were conducted with oncologists, clinical trial investigators, health economics specialists, regulatory affairs experts, and supply chain leaders to capture experiential insights and operational challenges.

Data triangulation methods linked qualitative interview findings with published evidence to validate emergent themes and identify gaps in the public record. Segmentation analyses were applied to clinical, distribution, and end-user dimensions to illuminate differentiated adoption pathways. Limitations of the methodology include the rapidly evolving nature of clinical data, regional variability in regulatory timelines, and the potential for emerging trial results to alter competitive dynamics; to mitigate these, the study highlights areas for ongoing surveillance and recommends periodic updates to maintain relevance.

Where appropriate, the methodology prioritized transparency in source selection and analytic assumptions, enabling stakeholders to assess the provenance of key findings and to adapt the approach for bespoke analyses focused on particular geographies, mechanisms, or therapeutic combinations.

Concluding synthesis that crystallizes strategic implications from clinical innovation, policy shifts, and operational priorities for lung cancer immunotherapy stakeholders

The convergence of scientific innovation, strategic commercialization tactics, and policy evolution is reshaping how immune checkpoint inhibitors are developed and used in lung cancer care. Clinically, biomarker-driven selection and combination regimens are refining therapeutic benefit while introducing new complexities for safety management and trial design. Operationally, distribution channel choice and end-user readiness influence access, and resilient supply chains are essential to preserve continuity of care in the face of policy shocks.

From a strategic perspective, companies that integrate diagnostic strategies, invest in robust real-world evidence programs, and engage payers proactively will be better positioned to achieve durable adoption. Regional differentiation requires tailored evidence packages and localized execution plans to accommodate varying regulatory and reimbursement landscapes. Collectively, these insights underscore that success in this therapeutic area hinges on coordinated efforts across clinical development, evidence generation, manufacturing, and payer engagement.

In closing, the evolving immunotherapy landscape presents substantial opportunities to improve patient outcomes, but realizing those gains requires disciplined strategy, operational resilience, and sustained collaboration among industry, clinicians, and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immune Checkpoint Inhibitors for Lung Cancer Market, by Cancer Type

  • 8.1. Cancer Type
    • 8.1.1. Non-Small Cell Lung Cancer
      • 8.1.1.1. Non-Squamous
      • 8.1.1.1.1. Adenocarcinoma
      • 8.1.1.1.2. Large Cell Carcinoma
      • 8.1.1.2. Squamous
    • 8.1.2. Small Cell Lung Cancer

9. Immune Checkpoint Inhibitors for Lung Cancer Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy
  • 9.4. Specialty Pharmacy

10. Immune Checkpoint Inhibitors for Lung Cancer Market, by Treatment Regimen

  • 10.1. Combination Therapy
    • 10.1.1. With Chemotherapy
    • 10.1.2. With Targeted Therapy
  • 10.2. Monotherapy

11. Immune Checkpoint Inhibitors for Lung Cancer Market, by Mechanism Of Action

  • 11.1. CTLA-4 Inhibitor
  • 11.2. PD-1 Inhibitor
    • 11.2.1. Cemiplimab
    • 11.2.2. Nivolumab
    • 11.2.3. Pembrolizumab

12. Immune Checkpoint Inhibitors for Lung Cancer Market, by Line Of Therapy

  • 12.1. First Line
  • 12.2. Second Line
  • 12.3. Third Or Later

13. Immune Checkpoint Inhibitors for Lung Cancer Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Home Care Settings
  • 13.3. Hospitals
  • 13.4. Oncology Clinics

14. Immune Checkpoint Inhibitors for Lung Cancer Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Immune Checkpoint Inhibitors for Lung Cancer Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Immune Checkpoint Inhibitors for Lung Cancer Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Immune Checkpoint Inhibitors for Lung Cancer Market

18. China Immune Checkpoint Inhibitors for Lung Cancer Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. AstraZeneca plc
  • 19.7. Bayer AG
  • 19.8. BeyondSpring Pharmaceuticals Inc.
  • 19.9. BioLineRx Ltd.
  • 19.10. BridgeBio Inc.
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Celgene Corporation
  • 19.13. F. Hoffmann-La Roche AG
  • 19.14. Genentech, Inc.
  • 19.15. IQVIA Inc.
  • 19.16. Jazz Pharmaceuticals
  • 19.17. Mirati Therapeutics Inc.
  • 19.18. Ono Pharmaceutical Co. Ltd
  • 19.19. Philogen S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 208. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 211. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 214. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 244. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 247. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 249. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 250. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 256. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 259. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 261. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 262. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)